Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Concert Pharmaceuticals, Inc.
Concert Pharmaceuticals Initiates CTP-347 Phase I Clinical Trial
October 9th, 2008
Concert Pharmaceuticals, Inc. announced that it has initiated a Phase I study in healthy volunteers to evaluate the safety, tolerability and pharmacokinetics of CTP-347, a novel deuterium-containing serotonin modulator created by Concert researchers. Concert intends to evaluate CTP-347 as a non-hormonal treatment for vasomotor symptoms (VMS or hot flashes) in patients with increased risk of adverse effects due to, or contraindicated to using, hormone therapy, as well as in the larger menopausal population. Results of this Phase I study are expected to be available in the first half of 2009. "We are pleased to have advanced our first compound from concept to clinical...
Source: Women's Health Weekly (2008-10-09)
|
